Granata Bio, a Boston, MA-based biotechnology company focused on advancing fertility therapeutics, received an investment from Gedeon Richter.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO Evan Sussman, Granata Bio is a biopharmaceutical company which specializes in women’s health and infertility. Its pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine.
The company is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing therapeutics aimed at preserving ovarian function and extending female health span.
FinSMEs
15/05/2025